HC Wainwright Issues Positive Estimate for BCTX Earnings

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Stock analysts at HC Wainwright boosted their Q2 2025 earnings estimates for BriaCell Therapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($1.94) per share for the quarter, up from their prior forecast of ($4.05). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($15.14) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($2.45) EPS, FY2026 earnings at ($1.47) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.69) EPS and FY2029 earnings at ($0.24) EPS.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings data on Monday, December 16th. The company reported ($3.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.10).

BriaCell Therapeutics Stock Performance

Shares of BCTX opened at $4.05 on Wednesday. BriaCell Therapeutics has a 1 year low of $3.92 and a 1 year high of $63.75. The company has a market cap of $11.95 million, a price-to-earnings ratio of -0.30 and a beta of 1.59. The firm has a fifty day moving average of $8.62 and a 200-day moving average of $10.28.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. grew its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 37.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 110,000 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Vontobel Holding Ltd. owned about 0.25% of BriaCell Therapeutics worth $62,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.